Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics
Zacks Investment Research | Jan 06, 2022 09:30PM ET
Illumina (NASDAQ:ILMN), Inc. ILMN and SomaLogic have recently signed a definitive co-development agreement to bring the SomaScan Proteomics Assay to Illumina's existing and future high throughput next-generation sequencing (NGS) platforms. Researchers can effectively and efficiently make biological connections from the genetic sequence (genotype) to cellular function (phenotype) with the help of the scale and speed of Illumina NGS technology, thereby advancing opportunities for clinical impact. This collaboration is set to bolster the fast-growing high throughput sector of the proteomics market.
Under the terms of the agreement, Illumina will commence a multi-year development effort to combine SomaLogic's protein target volume with its sequencing technologies, informatics toolsets and DRAGEN software to develop a complete end-to-end NGS workflow solution. The development will help researchers to have access to a more cost-effective, high throughput read-out capability for their multiomic assays on the same platform.
The collaboration is likely to boost Illumina's portfolio of sequencing platforms.
h3 Strategic Significance/h3Although proteomics is a natural extension of genomics, it has been rather difficult to conduct proteomics experiments at scale, with large quantities of proteins (ultra-high plexity) and large numbers of samples (ultra-high throughput). However, Illumina’s recent collaboration will enable researchers to evaluate thousands of samples for more than 10,000 protein targets by combining the power of high-plexity Somascan technology with its existing and future high throughput NGS platforms. Through easy, automated analysis and cost efficiencies, the partnership will gradually expand this capability over time.
Per Illumina management, proteins play a critical role in cellular function and health. NGS can help form a greater understanding of this role by unlocking biological insights at scale. The collaboration between Illumina and SomaLogic will facilitate and empower proteomics and multiomics research.
h3 Industry Prospects/h3
AMN Healthcare, carrying a Zacks Rank #1, has a long-term earnings growth rate of 16.2%. The company’s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 19.5%, on average.
AMN Healthcare has outperformed its industry over the past year. AMN has gained 65.8% versus the 55.8% industry decline.
Apollo Endosurgery, carrying a Zacks Rank #2 (Buy), has a long-term earnings growth rate of 7%. The company‘s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 25.6%, on average.
Apollo Endosurgery has outperformed its industry in the past year. APEN has gained 112.3% compared with the industry’s 1.4% fall.
Abbott, sporting a Zacks Rank #2, has a long-term earnings growth rate of 12%. The company’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 18.5%.
Abbott has outperformed its industry in the past year. ABT has rallied 21.1% compared with the industry’s 8.6% fall.
Get The News You Want
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
As one investor put it, “curing and preventing hundreds of diseases…what should that market be worth?” This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer (NYSE:SAM) Company which shot up +143.0% in little more than 9 months and NVIDIA (NASDAQ:NVDA) which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.